लोकसभा चुनावों से पहले इन शेयरों पर लगाएं दांव

तीन राज्यों में चुनावी शिकस्त के बाद भाजपा अपने पक्ष में लहर को मोड़ने की कोशिश करेगी. इसके चलते केंद्र सरकार 2019 के आम चुनाव तक लोकलुभावन नीतियों को अपना सकती है. विश्लेषकों ने ऐसी उम्मीद जताई है. यही वजह है कि विश्लेषकों ने निवेशक को खपत से जुड़े शेयरों में निवेश की सलाह देना शुरू कर दिया है. उन्हें खासतौर से एफएमसीजी, व्हाइट गुड्स, इलेक्ट्रिकल एंड इलेक्ट्रॉनिक्स और एग्रो-केमिकल सेक्टर के शेयरों में पैसा लगाने की राय दी जा रही है.

To Get Free Trial 
Missed call @ 8817002233 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = https://www.starindiaresearch.com/freetrial

Bitter Pill! Pharma stocks drag 1.6%

Shares of Pharmaceutical companies slipped on the BSE and NSE. Wockhardt cracked 6% to Rs533 on BSE after a media report that the US court invalidated company's patent in Prostate cancer drug Zytiga

To Get Free Trial 
Missed call @ 8817002233 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php

Sun Pharma Q2FY19 Result Expectation

Sun Pharma is expected to report 14.8%/11.3% yoy growth in revenue/PAT to Rs7,633cr/Rs1,015cr respectively. 

Consensus estimates for Q2FY19 

• Revenue – Expected to grow 14.8% yoy to Rs7,633cr due strong US business and rupee depreciation. Sun Pharma’s India revenue is expected to grow 4% yoy in Q2FY19 due to the higher base in Q2FY18. US revenue is expected to grow 22.5% yoy to $379mn due to launches of gWelchol, gNexium, Methadone HCL, etc. as well as two specialty product launches. Taro reported 6.4% yoy revenue decline due to continued competition and US pricing pressure. 
• EBITDA – Expected 20.6% yoy growth to Rs1,660cr in Q2FY19 due to stable price erosion and recent product launches. EBITDA margins estimated to expand by 100bps yoy to 21.7% in Q2FY19. 
• Net profit - PAT likely to grow 11.3% yoy to Rs1,015r. 

Q1FY19 performance highlights 

• Revenue – grew 16.4% yoy to Rs7,224.2cr. EBITDA – grew by 46.6% yoy to Rs1,606.7cr, EBITDA margins grew by 459 bps yoy to 22.2% in Q1FY19. 
• Net profit – stood at Rs1110cr vs. loss of Rs320cr in Q1FY18.

To Get Free Trial 
Missed call @ 8817002233 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php

Lupin Q2FY19 Result Expectation

Lupin is expected to report continued weakness in its US business due to higher competition in its large generic products. We expect 5% yoy growth in revenue while EBITDA and PAT are expected to decline 29% and 37% yoy, respectively.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php

Dilip Buildcon gains 2% on order wins worth Rs601cr

Shares of Dilip Buildcon (DBL) were trading 2% up in Tuesday’s morning session after receiving an order worth Rs601cr from the Water Resource Department, Kota, Rajasthan. "DBL has been declared as L-1 bidder for a new EPC project Navnera Barrage (Dam) under phase 1/A valued at Rs601.02cr by the Water Resource Department, Kota, Rajasthan," the company said in a press note to the exchanges on Monday after market hours.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php

TCS hits new high; Infosys up 3% in a weak market

Shares of information technology (IT) companies were trading higher in an otherwise weak market on Monday after the Reserve Bank of India (RBI) shortlisted five IT firms including Infosys and Tata Consultancy Services (TCS) for implementation of a centralised information and management system (CIMS) for seamless data collection and validations.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php

Sun Pharma, SPARC gain 3-7% on USFDA approval for Xelpros

Shares of Sun Pharmaceutical Industries and Sun Pharma Advanced Research Company gained 3-7 percent in the opening trade on Friday on the back of USFDA approval for Xelpros which is used to treat open-angle Glaucoma or Ocular Hypertension.

The company announced USFDA (US Food and Drug Administration) approval for the new drug application (NDA) of Xelprostm (latanoprost ophthalmic emulsion) 0.005% for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

This approval is from Sun Pharma’s Halol (Gujarat, India) facility.

To Get Free Trial 
Missed call @ 9582541010 
Call Us @ 8822117117 
Mail Us = starindiamarket@gmail.com 
Visit = http://www.starindiaresearch.com/freetrail.php